Tarsus Pharmaceuticals
TARS
195 hedge funds and large institutions have $2.23B invested in Tarsus Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 65 increasing their positions, 55 reducing their positions, and 22 closing their positions.
164% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 22
56% more capital invested
Capital invested by funds: $1.43B → $2.23B (+$802M)
20% more funds holding
Funds holding: 162 → 195 (+33)
18% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 55
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
8.75% less ownership
Funds ownership: 114.07% → 105.31% (-8.8%)
74% less call options, than puts
Call options by funds: $4.57M | Put options by funds: $17.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$86.7M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$31.1M |
| 3 |
Millennium Management
New York
|
+$19.1M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$18M |
| 5 |
Jennison Associates
New York
|
+$14.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$50.4M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$29M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$19.4M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$19.2M |
| 5 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
-$18.8M |
TARS Hedge Fund Activity: Q4 2024 in Review
195 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q4 2024, worth a combined $2.23B — up 56% from $1.43B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new TARS positions and 22 closed out — a net gain of 36 holders — while 65 added to existing stakes and 55 trimmed.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $86.7M. The largest seller was Perceptive Advisors, cutting an estimated $50.4M.
- 195 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q4 2024, up from 162 in Q3 2024.
- Funds reported $2.23B of Tarsus Pharmaceuticals stock for Q4 2024, up 56% quarter-over-quarter.
- 58 funds opened new Tarsus Pharmaceuticals positions in Q4 2024 and 22 closed out, a net change of +36 holders.
- The largest Tarsus Pharmaceuticals buyer in Q4 2024 was Toronto Dominion Bank, an estimated $86.7M added.
- The largest Tarsus Pharmaceuticals seller in Q4 2024 was Perceptive Advisors, an estimated $50.4M sold.
Based on aggregated 13F filings for Q4 2024.